Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics' Q1 Revenues Increase 40 Percent

NEW YORK (GenomeWeb News) – Molecular diagnostics company Response Genetics today reported a 40 percent increase year over year in its first-quarter revenues.

The Los Angeles-based company said that for the three months ended March 31, revenues rose to $5.6 million from $4.0 million. Revenues from its pharmaceutical clients increased 137 percent year over year, while revenues generated by ResponseDX products rose 8 percent.

Response Genetics' net loss in the quarter dropped to $$824,304, or $.03 per share, from a net loss of $3.1 million, or $.14 per share, a year ago. The company used about 33 million shares in calculating its per-share loss for the recently completed quarter, compared to 23 million shares a year ago.

Response Genetics placed 8 million new shares of its stock in September with GlaxoSmithKline and a "significant" shareholder, raising $8.8 million.

The firm's R&D costs were cut 48 percent year over year to $297,200 from $569,955, and SG&A costs were trimmed 5 percent to $3.6 million from $3.8 million.

Response Genetics finished the quarter with $8.0 million in cash and cash equivalents.

"Despite the pricing headwinds brought about by Medicare in 2013, we have managed to once again grow our Dx revenues while maintaining strong gross margins," Response Genetics Chairman and CEO Thomas Bologna said in a statement.

"As we continue to leverage our strong balance sheet to invest in sales and marketing, we expect to deliver meaningful top-line growth in our Dx business in the second half of 2013. We believe recent additions to both our sales force infrastructure and sales and marketing management, coupled with a constant focus on cost structure and operational efficiencies, which were the hallmarks of our 2012 turnaround, will help further drive our strategic and financial performance," he continued.

In Tuesday morning trading on the Nasdaq, shares of Response Genetics were down 3 percent at $1.18.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.